US equities |
NVDA $239.92 ▲+0.43% SPCX $173.57 ▲+1.45% MU $1,065.44 ▲+0.14% MRVL $287.88 ▲+6.13% AMD $654.90 ▲+3.66% INTC $114.30 ▼-1.63% AVGO $380.33 ▲+4.92% SNDK $1,675.60 ▼-1.68%
FinancialContent

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

23.77 -1.55 (-6.12%)
Delayed Quote Updated: 1:44 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
The Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
STOKE THERAPEUTICS INC (NASDAQ:STOK) – A Biotech Stock with Strong Growth Signals ↗
STOKE THERAPEUTICS (NASDAQ:STOK) shows strong growth metrics, high profitability improvements, and attractive valuation, making it a candidate for growth investors following Louis Navellier's... 
Via Chartmill
News headline image
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar ↗
The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs. 
Via Investor's Business Daily
Topics Earnings
News headline image
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics ↗
 
Via Benzinga
News headline image
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces CEO Transition
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present at Upcoming Investor Conferences in March
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal ↗
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments. 
Via Benzinga
News headline image
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
From Biogen Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics
Via Business Wire
News headline image
Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present at Upcoming Investor Conferences in September
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >